Swedish study reports low vision loss risk with GLP-1RAs
1. In this cohort study, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with a higher risk of anterior ischemic ...
Tag: SGLT-2 inhibitors
GLP-1RAs may increase ischemic optic neuropathy risk
1. In this target trial emulation, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with a small increase in the ...
GLP-1RAs showed no advantage for basal insulin discontinuation
1. In this target trial emulation, initiating a glucagon-like peptide-1 receptor agonist (GLP-1RA) was not associated with higher rates of ...
#VisualAbstract: Dapagliflozin Reduced Death and Worsening Heart Failure in Transcatheter Aor-tic-Valve Implantation
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Similar neuroprotective effects from sodium-glucose cotransporter-2 inhibitors and dulaglutide
1. In this target trial emulation study of older adult patients with type 2 diabetes, those who received sodium-glucose cotransporter-2 ...
Sodium-glucose cotransporter 2 inhibitor use in patients with type 2 diabetes linked to decreased risk of nephrolithiasis
1. A reduced risk of nephrolithiasis was linked with patients with type 2 diabetes (T2D) initiating sodium-glucose cotransporter 2 inhibitor ...
SGLT2 inhibitors reduce recurrent flares and hospitalizations in patients with gout
1. In this population cohort study, patients with gout who used sodium-glucose cotransporter-2 inhibitors (SGLT2is) experienced fewer recurrent flares than ...
Sodium-glucose cotransporter-2 inhibitors are of intermediate or low economic value in the treatment of heart failure with preserved ejection fraction
1. Sodium-glucose cotransporter-2 inhibitors (SGLT2-I) in combination with standard of care were found to increase quality-adjusted life-years at a cost ...
SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes
1. SGLT2 inhibitors reduced the risk of kidney disease progression by 37% overall, with comparable effects in patients with and ...
#VisualAbstract: Treatment with empagliflozin reduced progression of chronic kidney disease
Click here to read this study in NEJM
